An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Spruce Biosciences to Participate in March Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Spruce Biosciences (NASDAQ: SPRB), a late-stage biopharmaceutical company, announced its participation in two virtual investor conferences in March 2022. The Cowen 42nd Annual Health Care Conference will occur from March 7-9, featuring a company presentation on March 9 at 11:10 a.m. ET. The Oppenheimer 32nd Annual Healthcare Conference will take place from March 15-17, with a fireside chat on March 16 at 8:00 a.m. ET. Webcasts of these events will be accessible on the company's investor relations website.
Positive
None.
Negative
None.
SAN FRANCISCO--(BUSINESS WIRE)--
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place virtually in March.
Cowen 42nd Annual Health Care Conference Date:March 7-9, 2022 Format:Company presentation (March 9 at 11:10 a.m. ET) and 1x1 meetings
Oppenheimer 32nd Annual Healthcare Conference
Date:March 15-17, 2022 Format:Fireside chat (March 16 at 8:00 a.m. ET) and 1x1 meetings
Interested parties can access the webcast for each conference presentation from the Events section of the company’s investor relations website at https://investors.sprucebiosciences.com. A replay of the webcasts will be available after the conclusion of the live presentations for approximately 30 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.
When is Spruce Biosciences participating in the Cowen conference?
Spruce Biosciences will participate in the Cowen 42nd Annual Health Care Conference from March 7-9, 2022, with a presentation scheduled for March 9 at 11:10 a.m. ET.
What is the date for Spruce Biosciences' Oppenheimer conference participation?
Spruce Biosciences will take part in the Oppenheimer 32nd Annual Healthcare Conference from March 15-17, 2022, with a fireside chat on March 16 at 8:00 a.m. ET.
How can I access the webcasts for the Spruce Biosciences conferences?
The webcasts for the Spruce Biosciences conferences can be accessed on the company’s investor relations website.
What is the main focus of Spruce Biosciences?
Spruce Biosciences focuses on developing novel therapies for rare endocrine disorders with significant unmet medical needs.
What is tildacerfont's significance for Spruce Biosciences?
Tildacerfont is Spruce Biosciences' primary product candidate, aimed at treating classic congenital adrenal hyperplasia and a form of polycystic ovary syndrome.
